EU/3/17/1940: Orphan designation for the treatment of haemophilia B

Concizumab

Overview

On 12 October 2017, orphan designation (EU/3/17/1940) was granted by the European Commission to Novo Nordisk A/S, Denmark, for concizumab for the treatment of haemophilia B.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2022 on request of the Sponsor.

Key facts

Active substance
Concizumab
Intended use
Treatment of haemophilia B
Orphan designation status
Withdrawn
EU designation number
EU/3/17/1940
Date of designation
12/10/2017
Sponsor

Novo Nordisk A/S
Novo Alle 1
2880 Bagsvaerd
Denmark
Tel. +45 4444 8888
E-mail: webmasters@novonordisk.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

DateUpdate
December 2022The product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating